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Colorectal cancer is usually considered a disease of the elderly. However, a small fraction of patients develops colorectal cancer
earlier. The aim of our study was to define the frequency of known hereditary colorectal syndromes and to characterise genetic
and epigenetic features of early nonhereditary tumors. Thirty-three patients ≤40 years with diagnosis of colorectal cancer and
41 patients with disease at >60 years of age were investigated for MSI, Mismatch Repair proteins expression, KRAS and BRAF
mutations, hypermethylation, and LINE-1 hypomethylation. Detection of germline mutations was performed in Mismatch Repair,
APC andMUTYH genes. Early onset colorectal cancer showed a high incidence of hereditary forms (18%). KRASmutations were
detected in 36% of early nonhereditary tumors. Early onset colorectal cancer disclosed an average number of methylated genes
significantly lower when compared to the controls (𝑝 = 0.02). Finally both of the two groups were highly methylated in ESR1,
GATA5, andWT1 genes and were similar for LINE-1 hypomethylation. The genetic make-up of carcinomas differs from young to
elderly patients. Early onset tumors showed more frequently a constitutional defective of Mismatch Repair System and a minor
number of methylated genes. Hypermethylation of ESR1,GATA5, andWT1 genes suggests possible markers in the earlier diagnosis
of colorectal tumorigenesis.
1. Introduction
Colorectal cancer (CRC) is the second most common cancer
in both men and women inWestern Europe, North America,
Australia/New Zealand, and Japan, whereas it remains less
frequent in Africa and Asia [1]. Colorectal cancer is usually
considered a disease of the elderly in both sexes; data from
Cancer Registries indicate that age-specific cancer incidence
rises sharply after the age of 50–55 years and that mean age
of affected individuals is around 70 years [2]. However, in a
small fraction of patients (2-3% of all affected individuals),
colorectal malignancies may develop earlier [3].
A review of the Surveillance Epidemiology and End
Results (SEER) Program data from 2005 to 2009 provides
more detailed information regarding colorectal cancer in
younger patients suggesting that the incidence in younger
patients is increasing along time (ages <20 to 54 years)
[4], whereas other data would show a relative stability of
the rates [5]. Part of these discrepancies can be attributed
to the different age-limits proposed for the definition of
early onset (or “juvenile”) tumors, which have been set at
age 40, 45, or 50 depending on the authors and purposes
of the studies [6, 7]. Although there is no clear age cut-
off defined, the majority of studies classify patients diag-
nosed with cancer at age <40 years as “early onset” (or
“young”) [8]. The reasons whereby some individuals develop
colorectal cancer at an unusual age are poorly understood.
Therefore, the etiology and biological characterisation of the
majority of early onset colorectal neoplasms remain poorly
defined.
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2015, Article ID 132190, 10 pages
http://dx.doi.org/10.1155/2015/132190
2 Gastroenterology Research and Practice
From a molecular point of view, early onset tumors
represent a heterogeneous group of diseases, including
known hereditary syndromes, familial cases, and appar-
ently sporadic colorectal cancer. Hereditary diseases explain
only part of early onset colorectal cancer [9] and mainly
include Lynch syndrome [7, 10–12], Familial Adenomatous
Polyposis (FAP) [13], Peutz-Jeghers syndrome [14], Cowden
syndrome/Bannayan [15], andMUTYH-associated polyposis
(MAP) [13, 16].
Recent studies have suggested that the clinic-pathologic
features related to early onset colorectal cancer [7] are
more likely to be present at advanced stages, to be poorly
differentiated, and to be located in the distal colon and in
the rectum, although marked differences have never been
reported.Morphologically, early onset CRCsmore frequently
display adverse histological features, such as signet ring
cell differentiation and perineural and venous invasion [9].
Investigation of somatic profiles showed an increasing num-
ber of tumors with KRAS, BRAF, and PIK3CA oncogenes
mutations related to advanced age. Mutations in the tumor
suppressor genes TP53 and PTEN were more frequent in the
early onset group [17]. Other findings showed that young
patients had significantly more chromosomal aberrations in
their tumors than patients aged >70 years and microsatellite
stable (MSS) colorectal cancer [7, 17, 18]. Recently, LINE-1
hypomethylation has been reported to be a distinct feature
of MSS young age colorectal cancers (≤45 years), suggesting
that the genomic hypomethylation may represent a possible
pathway of early onset colorectal carcinogenesis [19]. By
contrast, very few data are available about the frequency
of CpG island methylator phenotype (CIMP) in early onset
CRCs [19].
The knowledge about this clinically and genetically
heterogeneous group of colorectal cancers remains limited
and further studies are essential. To address this issue, we
conducted a population based case-control study on CRCs
diagnosed before the age of 40 years in order to define
the frequency of known hereditary CRC syndromes in this
subset of patients and to better characterize genetic and
epigenetic features of early nonhereditary tumors compared
with sporadic late onset CRCs.
2. Materials and Methods
2.1. Patients. The patients described in this study were
recruited through the specialized Colorectal Cancer Registry
of Modena in the period 1984–2008. In the 25 years of regis-
tration, we recruited 38 patients affected by adenocarcinoma
in the colon-rectum diagnosed ≤40 years, which represented
about 1% of the overall adenocarcinomas diagnosed (4,692
cases). We collected the biological material (blood sample,
normal colorectal mucosa, and tumoral tissue) of 33 cases out
of 38 and investigated the family history relative to the cases,
including at least first-degree or second-degree relatives.
In order to compare some molecular features—including
methylation of DNA—of early onset colorectal cancer with
maturity onset disease, we selected a specific control group
composed of 41 patients with late onset colorectal cancer
(age-range: 61–85 years) that were matched to the study
group for the following characteristics: sex, tumor location,
and stage. Family cancer history was not present in late
onset group. Tumors were classified as low-grade and high-
grade adenocarcinoma [20] and staged with the Dukes’
classification.
The study was approved by the local ethics committee.
All individuals, or first-degree relative in case of death of the
index case, gave their written consent for blood samples and
tissue specimen analysis.
2.2. DNA Extraction. Genomic DNA from each patient
was extracted by formalin-fixed, paraffin-embedded normal
and tumor tissues. Serial sections from paraffin-embedded
matched normal and neoplastic primary tissue were stained
with Hematoxylin-eosin; representative normal and tumor
regions were identified by microscopic examination. Areas
of tumor tissue with more than 80% of malignant cells were
selected in all cases, as previously described in detail [21].
Constitutional DNA from peripheral blood was obtained
using QIAamp DNA Mini kit (Qiagen), according to the
manufacturer’s instructions.
2.3. MSI Analysis. MSI status of all tumors was evalu-
ated using four fluorescent-labeledmononucleotidemarkers:
BAT25, BAT26, NR24, and CAT25. These quasimonomor-
phic markers were selected after in-depth review of the
literature for their very high sensitivity and specificity in
identifying Mismatch Repair-deficient tumors [22–24]. The
resulting panel composed of four markers reduced the time
and cost involved in MSI testing. Other authors as Xicola
and Deschoolmeester suggested a MSI analysis shortcut [23,
24]. Using this mononucleotide markers panel, a tumor was
defined asMSI(+)when showing instability with at least three
markers.MSI analysis was performed as described previously
[21].
2.4. Immunohistochemical Analysis of MMR Proteins.
Immunohistochemical (IHC) evaluation of MMR proteins
expression was carried out on paraffin-embedded tissue
sections of all tumors. The following mouse monoclonal
antibodies were used: anti-MLH1, anti-MSH2 (PharMingen,
San Diego, CA), and anti-MSH6 Transduction Laboratories,
BD Biosciences, Brazil. For PMS2 protein, a rabbit
monoclonal antibody was used (Ventana Roche Diagnostic,
Italy). Immunostaining was executed by the avidin-biotin
peroxidase technique; diaminobenzidine was used as a
chromogen. Staining was carried out in NEX-ES Automatic
Staining System, after counterstaining with Hematoxylin.
Normal tissue and stromal cells or lymphocytes adjacent to
the respective tumor were used as internal positive controls.
Loss of MMR proteins expression was defined as complete
absence of nuclear staining in tumor cells (but maintained in
normal epithelial and stromal cells).
2.5. Analysis of Germline Mutations in MMR, APC, and
MUTYH Genes. Cases showing MSI and lack of expression
of one ofMMR proteins in tumors were investigated to detect
germline mutations in MMR genes. Patients with clinical
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features of Familial Adenomatous Polyposis were assessed
for APC gene and all young patients were screened for the
presence of MUTYH gene mutations. Analysis of germline
mutations was performed by direct sequencing of the PCR
products obtained using the Dye Terminator Cycle Sequenc-
ing Kit (CEQ DTCS Kit, Beckman Coulter) and reactions
were run on aCEQ8000 capillary sequencer (BeckmanCoul-
ter). To exclude the possibility of large genomic rearrange-
ments inMMR genes, we usedMultiplex Ligation-Dependent
Probe Amplification (MLPA) procedure by SALSA P003-B2
kit (MRC-Holland, Amsterdam,Netherlands) and to confirm
results SALSA P248-A2 kit (MRC-Holland). The entire open
reading frame ofAPC gene was also analysed for the presence
of deletions or rearrangements by using the SALSA P043 kit
(MRC-Holland). Pathogenic mutations were detected twice
and confirmed in a second blood sample of the patient.
2.6. Somatic BRAF and KRAS Mutations Analysis. All 74
tumors were analysed for KRAS and BRAF activating muta-
tions. In KRAS, the more frequently mutated codons 12,
13, and 61 were analysed [25]. In BRAF gene, we amplified
exon 15 which includes the hot spot for mutation codon
600 (V600E). Mutation analysis was performed by direct
sequencingwith the use of the standard protocol and running
on Beckman Coulter CEQ 8000 instrument.
2.7. Methylation-Specific Multiplex Ligation-Dependent Probe
Amplification (MS-MLPA) Analysis. MS-MLPA analysis was
performed on all the 74 tumors (33 early onset CRC
and 41 control cases) using the ME001 MS-MLPA Tumor
Suppressor-1 Kit, the ME002 MS-MLPA Tumor Suppressor-
2 Kit, and the ME011 MS-MLPA Mismatch Repair Genes
Probemix Kit (MRC-Holland, Amsterdam, Netherlands).
Using these three kits, a total of 38 tumor suppressor genes
were analysed for aberrant promoter methylation. All these
genes are frequently silenced by methylation in tumors of
different sites, and they frequently harbour genetic alter-
ations during tumorigenesis. Methylation-specific MLPA
(MS-MLPA) is a semiquantitative method for methylation
profiling. MS-MLPA is a variant of the MLPA technique
in which copy number detection is combined with the use
of a methylation-sensitive restriction enzyme [26]. Probe
sequences, gene loci, and chromosome locations can be
found at http://www.mlpa.com.The experimental procedure
was carried out according to the manufacturer’s instruc-
tions. Reaction products were separated on an automated
sequencer (ABI 310 capillary) and visualised with Gen-
emapper analysis v.4.0 (Applied Biosystems). Values corre-
sponding to peak size (base pairs) and peak height were
used for further data processing by Coffalyser V7 software
(MRC-Holland). All MS-MLPA reactions were performed at
least two times. The methylation profile of each sample was
assessed according to MRC-Holland instructions.
Aberrant methylation was scored as a categorical variable
using a specific Methylation Ratio (MR) for each gene
corresponding to the highest level of accuracy of the test,
according to previously reported [27].
2.8. LINE-1 PCR and Pyrosequencing. Themethylation status
of LINE-1 was evaluated by bisulfite-PCR and pyrosequenc-
ing [28] in all tumors and in twenty-five samples of normal
colonic mucosa. Thirteen of these samples were derived
from normal tissue at the resection margins of 13 patients
with sporadic CRCs. The remaining normal specimens were
obtained from 12 individuals who had undergone surgery
for ischemic colorectal disease or for diverticulitis without
a personal history of colorectal cancer. Bisulfite treatment
of genomic DNA converts all unmethylated cytosines into
thymine while methylated cytosines remain unchanged. All
the cytosine residues unconverted in the sequence represent
methylated cytosines in the genome. In this method, 1.5mg
of DNAwas denatured in 50mL of 0.2MNaOH for 10min at
37∘C. Then, 30mL of freshly prepared 10mM hydroquinone
and 520mL of 3M sodium bisulfite at pH 5.0 were added
and mixed. The samples were incubated at 50∘C for 16 h. The
bisulfite-treatedDNAwas purified usingWizardDNAClean-
Up System (Promega).
LINE-1 assay was designed toward a consensus LINE-1
sequence (GenBank accession number X58075) and allowed
to quantify the percentage of 5-methylated cytosines (%5mC)
in five consecutive CpG sites. PCR was performed in a
50 𝜇L reaction volume that included 2 pmol of forward
primer 5󸀠-GAGTTAGGTGTGGGATATAGT-3󸀠, 2 pmol of
reverse biotinylated primer 5󸀠-CAAAAAATCAAAAAA-
TTCCCTTCCC-3󸀠, 5 𝜇L of bisulfite-treated genomic DNA
1.25 units of GoTaq DNA polymerase, 1X GoTaq Flexi
Buffer (Promega, Madison, WI, USA), and 200𝜇M dNTPs.
Thermal cycling conditions were 3min at 95∘C, 45 cycles
at 95∘C/25 s, 50∘C/25 s, and 72∘C/25 s, followed by a final
extension at 72∘C for 5min. Pyrosequencing was performed
on PCR product with bound LINE-1 sequencing primer
5󸀠-GGTGTGGGATATAGTT-3󸀠, according to the protocol
reported above. Fully methylated DNA (CpGenome Univer-
sal Methylated DNA, Millipore, Billerica, MA, USA) and
unmethylated DNA (CpGenome Universal Unmethylated
DNA, Millipore, Billerica, MA, USA) were used as positive
and negative controls for optimizing the assay.
2.9. Statistical Analysis. Univariate comparisons of continu-
ous data were carried out using Student’s 𝑡-test and discrete
variables were compared with 𝜒2 test or Fisher’s exact test.
The association between discrete outcome and continuous
predictor was evaluated with a logistic regression model.
All comparisons were two-sided and a 𝑝 value < 0.05 was
considered to be significant.
3. Results
3.1. Patients Features. We recruited a total of 38 patients with
adenocarcinoma in the colon-rectum diagnosed before the
age of 40 years, but the biological material was available for 33
patients. Clinicopathological features of the 33 colorectal ade-
nocarcinomas and patients are shown in Table 1. The mean
age of disease onset was 35 years. We observed that the male
gender was approximately 3 times more frequent than female
(76% versus 24%), tumor location was preferentially the left
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Table 1: Clinicopathological features of 33 colorectal adenocarcinomas (and patients) developed ≤40 years (1984–2008) compared to patients
with cancer onset >60 years.
Technical details Patients with onset ≤40 years,
𝑁 = 33 (%)
Patients with onset >60 years,
𝑁 = 41 (%)
Age of onset of disease
Min
Max
Mean
11
40
35
61
85
73
Sex FemaleMale
8 (24)
25 (76)
11 (27)
30 (73)
Tumor location in the large
bowel
Right colon
Left colon
Rectum
7 (21)
17 (52)
9 (27)
12 (29)
19 (47)
10 (24)
Stage (Dukes)
A
B
C
D
5 (15)
7 (21)
12 (37)
9 (27)
7 (17)
9 (22)
14 (34)
11 (27)
Tumor differentiation
Low-grade
High-grade
Mucinous
19 (58)
8 (24)
6 (18)
31 (76)
8 (19)
2 (5)
colon (52%), and C and D stages of Dukes (37% and 27%,
resp.) were more frequently represented. Fifty-eight percent
of early onset tumors were well or moderately differentiated.
Family history of colorectal cancer was present in 8 (24%)
patients: 2 with Bethesda criteria (patients with a first-degree
relative affected by colorectal cancer), 5 who fulfilled the
Amsterdam II criteria, and 1 with Familial Adenomatous
Polyposis. Clinical features of Cowden/Bannayan [29] and
Peutz-Jeghers syndromes [30] were not identified in any
patients.
3.2. MMR Deficiency and Somatic Mutations of KRAS
and BRAF Genes. MMR deficiency was evaluated by both
immunohistochemistry and MSI analysis in all 74 colorectal
cancers. MMR deficiency was defined as loss of protein
expression in any of the MMR proteins and/or having a MSI
tumor. Seven out of 33 (21%) early onset tumors showed MSI
and loss of expression of MMR proteins (4 for MLH1/PMS2
and 3 for MSH2/MSH6). By family history, 5 patients (≤40
years) with MMR deficient tumors fulfilled clinical features
of Lynch syndrome and 2 the Bethesda Criteria. Four out of
41 (10%) tumors in the control group (4 for MLH1/PMS2)
were MMR deficient. These 4 tumors diagnosed over the
age of 60 years showed somaticMLH1 hypermethylation and
V600E mutation in BRAF gene. No V600E mutations were
detected in MSS tumors with clinical onset at advanced age
or in early onset colorectal cancers. We found somaticMSH2
methylation in only one case (patient with germinal EPCAM
deletion) among 7 young patients showing MSI and loss
of MSH2/MSH6 protein expression. KRAS mutations were
found in 10 early onset tumors and in 4 cases of the control
group. Thus, tumors of juvenile cases showed more often
somaticKRASmutations (30% versus 10%).Molecular results
in the investigated patients are summarized in Table 2.
3.3. Germline MMR, APC, and MUTYH Mutations. We
identified 6 cases with sequence variants in either MLH1
(3 cases), MSH2 (1 case), EPCAM (1 case), or APC (1
case) (Table 3). For MLH1, we detected one insertion
mutation (p.Arg497ProfsX6) and two missense mutations
(p.Leu749Pro and p.Glu663Asp). These two missense vari-
ants were classified as Class 5 mutations (>99% likelihood
of pathogenicity) by Plon et al. [31]. For MSH2, we found
one nonsensemutation (p.Phe294X).Moreover, we identified
a large deletion of exons 8 and 9 in EPCAM gene, without
involvement of MSH2 promoter, using the P003-B2 MLPA
kit. This finding was confirmed by the P072-B1 MLPA kit
(MRC-Holland). Only one patient was affected by Familial
Adenomatous Polyposis and showed an insertionmutation in
APC gene at exon 15 (p.Arg924SerfsX16). Germline analysis
of MUTYH gene was carried out in the whole group of
young patients, but no monoallelic or biallelic alteration was
detected.
3.4. Gene-Specific DNA Methylation. MS-MLPA assay was
employed to evaluate the hypermethylation profiles relative to
tumors from early onset patients (𝑛 = 33) and control group
(𝑛 = 41).The average number ofmethylated genes was signif-
icantly higher in the control group compared with the young
group (5.025 versus 3.3, resp.) (𝑝 = 0.02, Figure 1(a)). By con-
trast, no significant differences were observed between young
and hereditary/suspect of hereditary cases (Figure 1(b)).
In the control group, we observed two main tumor sets
on the basis of the degree of methylation. The first group
consisted of 7 CRCs (17% of cases) showing high levels of
gene methylation, involving a mean percentage of 28% of the
promoters examined (ranging from 24% to 37%).The second
group included the remaining 34CRCs showing absent or low
level methylation involving a mean percentage of 9% of the
genes analysed (ranging from 0% to 20%) (Figure 2).
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Table 2: Molecular features of colorectal carcinomas in cases and in the control group.
Technical detail
Patients with onset ≤40 years
Control group >60 years,𝑁 = 41 (%)𝑁 = 33
Nonhereditary cases,
𝑁 = 25 (%)
Hereditary/suspect of hereditary
cases,𝑁 = 8 (%)
MMR alterations
MSI and no expression
MMR proteins 0 7 (88) 4 (10)
Methylation
MLH1 orMSH2 promoter
hypermethylation 0 1 (13) 4 (10)
Somatic mutations
KRASmutation 9 (36) 1 (13) 4 (10)
BRAF mutation 0 0 4 (10)
Germline mutations
MMR 0 5 (63) 0
APC 0 1 (13) 0
MUTYH 0 0 0
Table 3: Constitutional mutations in early onset colorectal cancer.
Cases Gene Mutation
Lynch syndrome 5
MLH1 (3)
c.2246T>C; p.Leu749Pro
c.1489dupC; p.Arg497ProfsX6
c.1989G>T; p.Glu663Asp
MSH2 (1) c.881 882delTT; p.Phe294X
EPCAM (1) Del ex 8-9 and seq in 3󸀠 to +3 kb
Familial Adenomatous Polyposis 1 APC c.2771 2772insT; p. Arg924SerfsX16
The seven CRCs exhibiting extensive gene methylation
included all the cases showing MSI and BRAF mutation and
MLH1methylation.
On the other hand, in the group of early onset tumors,
we did not detect any case with extensive gene methylation.
No methylation for the MMR genes was found in these
tumors, with the exception of the case with EPCAM gene
mutation (A34), which was methylated in the MSH2 gene.
Evaluating the hypermethylation frequency in single genes,
no significant differences were observed comparing early
onset patients and control group. By contrast, a very high
frequency of methylation was detected in ESR1, GATA5, and
WT1 genes in both groups of the familiarity (Figure 3).
3.5. LINE-1Hypomethylation. Weused the quantitative bisul-
fite pyrosequencing to determine the methylation status of
LINE-1 repetitive sequences in all CRCs compared to twenty-
five samples of normal colonic mucosa. In normal samples,
LINE-1methylation levels were high (average 60.78%± 0.4%)
and very similar to those commonly observed in peripheral
blood cells from normal individuals [32]. By contrast, LINE-
1 methylation levels in CRCs were significantly lower than in
normal samples (mean 55.4% ± 0.86; 𝑝 < 0.024).
Mean LINE-1methylation levels in the three study groups
of colorectal cancers were early onset, 54.3%; late onset,
55.9%; Lynch syndrome, 59.0% (Figure 4). The difference of
LINE-1 hypomethylation in early onset colorectal cancer was
not significant when compared to late onset ones. Interest-
ingly, in the Lynch syndrome tumors LINE-1 methylation
levels were higher than early onset and late onset groups and
similar in the mean percentage of normal mucosa. However,
this difference did not reach statistical significance because of
the small number of Lynch tumors.
4. Discussion
In this study we have assessed the clinicopathological, molec-
ular, and familial features of 33 early onset colorectal cancers
(≤40 years). We showed that the frequency of known heredi-
tary colorectal cancer syndromes in this population was 18%.
This cohort disclosed a molecular profile ofMMR deficiency
characterised by germline mutations in MLH1, MSH2, and
EPCAM genes, thus confirming that Lynch syndrome is the
most frequent cause of hereditary colorectal cancer in young
patients [12, 19].
Previous studies have revealed that colorectal cancer
diagnosed at early ages had a high probability of showing
MMR deficiency, ranging from 26% to 73% [11]. The reason
for this wide range could be explained by the different age
thresholds (from 24 to 50 years) and by diverse panels of
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Figure 1: Results of methylation status in young group and in elderly group. In (a), we observed a significant difference in methylation
pattern between patients under 40 yrs and patients over 60 yrs. The mean number of methylated genes in the control group is higher than
average number in the cases group. In (b), we observe no statistical difference between control, young, and hereditary cases, but the difference
remained significant between patients under 40 yrs and patients over 60 yrs.
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Figure 4: LINE-1 hypomethylation in early and late onset patients.
proteins analysed by IHC (usually restricted to MLH1 and
MSH2). Moreover, the majority of studies have analysed
either Lynch syndrome or sporadic colorectal cancer and
it is known that the rate of MSI is much lower in the
latter. Our study, based on a population based approach of
colorectal cancer developed ≤40 years recruited from the
specialised Colorectal Cancer Registry of Modena, showed
that the frequency of MMR deficiency was 21%. Although we
identified 7 tumors with MMR deficiency, we detected only
five patients with pathogenetic germline mutations in MMR
genes. Possible causes for the lack of identified constitutional
mutations could be low sensitivity of analytical methods or
genetic events [33] that affect both alleles of a MMR gene.
We did not identify any carrier ofMSH6 germline mutations.
Recent studies have shown that the average age of colorectal
cancer onset in MSH6 mutation carriers has been estimated
to be around 50 years, while MLH1 and MSH2 carriers
are diagnosed on average 10 years earlier [34]. Moreover,
mutations in theMSH6 gene have also been linked to a lower
risk of colorectal cancer and a higher risk of endometrial
carcinoma [34]. Although germline mutations ofMSH6 gene
in early onset colorectal cancer have been reported [35], this
difference in age of onset and associated riskmay explain why
MSH6mutations constitute a minor fraction of cases.
In summary, as suggested by Jasperson et al. [11], the study
of family cancer history, MSI, and IHC analyses followed by
germline genetic testing represent an effective procedure for
the diagnosis of Lynch syndrome in early onset cases.
Some population based studies showed that ∼30% of
biallelic MUTYH mutation carriers develop a colorectal
cancer in the absence of a polyposis phenotype [13, 16, 35].
Accordingly, it has been suggested that MUTYH testing
should be considered in early onset colorectal cancer patients
with intact DNA MMR, regardless of family history or
number of colonic polyps [13]. Gira´ldez et al. detected 2.8%
of biallelic MUTYH mutations in a cohort of 140 patients
with colorectal cancer diagnosed before the age of 50 [36]. In
our study we performed systematic whole-gene sequencing
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and did not find biallelic or monoallelicMUTYH mutations.
These negative results could be explained by the limited
number of investigated cases.
We identified only one pathogeneticmutation ofAPC in a
34-year-old patient with colorectal cancer and polyposis.The
literature describes that Familial Adenomatous Polyposis is
responsible for less than 1% of all colorectal cancers [37] and
that the mean age for colorectal cancer development in this
group of individuals is approximately 39 years [38], suggest-
ing that alsoAPC gene is implicated in cancer occurring at an
early age.
In agreement with that reported in literature, we observed
that 82% of early onset CRCs were not associated with known
hereditary CRC syndromes [36]. This subset of tumors
was mainly characterized by distal location, advanced stage,
and predominance of the male gender as well as other
investigators supported [39]. A previous study according to
Ahnen et al. reported that cancer-specific survival in patients
with young onset CRC is comparable to that of patients with
late onset cancer [5, 38]. Moreover, we observed a similar
frequency of somaticmutations forKRAS oncogene to overall
sporadic colorectal cancers that correspond to 40% [40].
Regarding BRAF gene, a recent study suggests that BRAF
mutations occur in 10–20% of sporadic colorectal cancer
and are closely associated with the MLH1 methylation. In
our young patients, no BRAF mutations or MLH1 promoter
methylation was detected.
A second important aspect of our work concerns the
analysis of aberrant hypo- and hyper-DNA methylation
profiles of early onset CRCs compared with late onset CRCs.
Both of these alterations are widely accepted as potential
source of early biomarkers for diagnosis and prognosis in
CRCs. CIMP phenotype, which accounts for almost 30–40%
[41], has rarely been evaluated in early onset CRCs. In our
work, no case with extensive gene methylation was observed
among early CRCs and the average number of methylated
geneswas significantly lower in these tumors (both hereditary
and nonhereditary CRCs) compared with the control group.
These results are in agreement with previous works
that reported low levels of gene hypermethylation in Lynch
syndrome cases [42, 43] as well as in nonhereditary early
onset CRCs [19].
In our study, extensive gene hypermethylation was
observed only in the late onset CRCs, accounting for 17%
of these cases. In agreement with literature, this subset of
CRCs frequently showedMSI and BRAFmutation andMLH1
methylation [41, 43].
For the first time, we demonstrated that hypermethyla-
tion of three genes, namely, ESR1,GATA5, andWT1, was very
common both in early onset (hereditary and nonhereditary
tumors) and in late onset CRCs. Although these results need
to be validated with further studies, our data have important
clinical implications suggesting the usefulness of aberrant
gene methylation analysis for the early detection and risk
assessment of CRC, without using age at onset as a differential
criterion. Promoter methylation analysis of serum and stool
DNA has the potential to be used as a noninvasive test for
the early diagnosis of CRC [44]. However, accurate selection
of methylation markers is crucial for sensitive and specific
detection of CRC as de novo methylation is also associated
with aging [45]. ESR1 is a well-known “type A” (age related)
gene because its hypermethylation is demonstrated in both
normal colorectal mucosa and CRCs, proportional to tissue
age. By contrast, GATA5 methylation has been reported as
a suitable marker for early diagnosis of CRC [46] and its
methylation is observed in colorectal adenomas but not in
inflammatory colorectal tissues.
Moreover, our analysis has highlighted the potential
utility of the WT1 gene as an early diagnostic marker of
CRC. To date, only a few studies have investigated WT1
methylation, confirming our data of widespread methylation
of this gene in CRCs [47, 48]. In our opinion, this finding
deserves to be explored further, especially with respect to the
aberrant mechanisms of loss of imprinting of 11p15 described
in CRCs and the possible link betweenWT1methylation and
the upregulation of IGF2 transcription [49].
Genome-wide hypomethylation is also reported as an
early event in CRC and it has been associated with the acti-
vation of protooncogenes (i.e., MET) [50] and the presence
of chromosomal instability [51]. Recently, Antelo et al. [39]
found significantly lower levels of LINE-1 methylation in
early onset CRCs compared to late onset CRCs, suggesting
that a high degree of LINE-1 hypomethylation is a unique
feature of CRCs in young patients. At variance, our study
does not confirm these previous findings, demonstrating very
similar LINE-1 methylation levels in early onset and in late
onset CRCs, with a normal distribution of LINE-1 values
in both subsets of tumors. In our opinion, several factors
may explain this discordance. Firstly, since the degree of
LINE-1 demethylation prognosis is linear in relation to TNM-
stage progression and this marker is a strong independent
factor for poor prognosis [52], the evaluation of tumor stage
is crucial when comparing different subsets of CRCs. The
second important point regards the tumor location because
lower levels of LINE-1 methylation have been reported in
distal compared with proximal CRCs [39]. Antelo et al.
examined two independent cohorts of CRCs developed ≤50
years including mainly advanced and distal CRCs without a
matched selection of the late onset CRCs. For these reasons
we designed a case-control study in which every early onset
CRC was matched with a late onset CRC for sex, location,
and stage. Finally, technical reasons may not be excluded,
although the same methodological approach has been used
in the two studies and very similar LINE-1 methylation levels
were observed considering normal colorectal mucosa and
MSI CRCs (both hereditary and sporadic tumors).
Moreover, Antelo et al. reported a similar result about
higher levels of LINE-1 methylation in Lynch syndrome
tumors than in group of early onset CRC. For this reason, it
is maybe not optimal to use this testing for detection of early
onset CRC, whereas Lynch syndrome is the most common
hereditary CRC in young patients. Although our series of
early onset CRCs is small and the present results are not
conclusive about this issue, we believe that the strong positive
association between LINE-1 hypomethylation and early onset
CRC previously reported needs to be reconsidered through
future larger case-control studies.
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5. Conclusion
The results of this study can be summarised as follows.
First, Lynch syndrome is the most frequent cause of
hereditary colorectal cancer in young patients; family can-
cer history, MSI, and IHC analyses followed by germline
genetic testing represent the most appropriate procedure for
Lynch syndrome diagnosis in early onset colorectal cancer.
Second, early onset colorectal cancers with MMR deficiency
were clinically and pathologically indistinguishable from
colorectal MSS carcinomas. Third, epigenetic events (hyper-
and hypomethylation) are not closely associated with early
onset colorectal cancer. Finally, our study emphasises that
the genetic basis in the majority of early onset colorectal
carcinomas remains unknown. Further studies of the whole
exome of this genetically undefined group of early onset
colorectal tumors will need to elucidate possible pathogenetic
mechanisms.
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